Søgning på udtrykket 'pseudomonas' giver 35 resultater
Nyt fra tidsskrifterne [+20]
Aktuelle smitsomme sygdomme [15]
Nyt fra tidsskrifterne [+20]
Der er mere end 20 resultater, måske du vil se
flere resultater her?
PLoS One Infectious Diseases
8.03.2023
ods for characterization of microbial production of polyhydroxyalkanoates (PHA) are currently under investigated, despite the advent of such systems in related fields. In this study, phenotypic microarray by Biolog PM1 screening of Halomonas sp. R5-57 and Pseudomonas sp. MR4-99 identified 49 and 54 carbon substrates to be metabolized by these bacteria, respectively. Growth on 15 (Halomonas sp. R5-57) and 14 (Pseudomonas sp. MR4-99) carbon substrates was subsequently characterized in 96-well plates using med
Trends in Microbiology
4.03.2023
l processes [1]. The environmental distribution of microbes is determined by microbial ecology, that is, the ecological interaction (see Glossary) of microbes with their environment, plants, animals, and each other. For a long time, intermicrobial relations were neglected in favor of understanding how individual microbes affected their hosts and surrounding environment. This has been most common for plant–microbe interactions, in which the bacterial genera Bacillus and Pseudomonas are heavily represented.
Antimicrobial Agents And Chemotherapy
1.03.2023
Antimicrobial Agents and Chemotherapy, Ahead of Print.
Antimicrobial Agents And Chemotherapy
23.02.2023
Antimicrobial Agents and Chemotherapy, Ahead of Print.
Infection
20.01.2023
. Abstract. . Background. P. aeruginosa bacteremia is a common and severe infection carrying high mortality in older adults. We aimed to evaluate outcomes of P. aeruginosa bacteremia among old adults (≥ 80 years). . . Methods. We included the 464/2394 (19%) older adults from a retrospective multinational (9 countries, 25 centers) cohort study of individ
Antimicrobial Agents And Chemotherapy
5.01.2023
Antimicrobial Agents and Chemotherapy, Ahead of Print.
Clinical Microbiology and Infection
28.12.2022
To evaluate the performance of commercially available tests to determine the susceptibility of multidrug resistant (MDR) clinical Pseudomonas aeruginosa strains to cefiderocol.
Infection
27.12.2022
. Abstract. . Background. P. aeruginosa bacteremia is a common and severe infection carrying high mortality in older adults. We aimed to evaluate outcomes of P. aeruginosa bacteremia among old adults (≥ 80 years). . . Methods. We included the 464/2394 (19%) older adults from a retrospective multinational (9 countries, 25 centers) cohort study of individ
Science Advances
7.12.2022
Science Advances, Volume 8, Issue 49, December 2022.
Proceedings of the National Academy of Sciences
5.12.2022
Proceedings of the National Academy of Sciences, Volume 119, Issue 50, December 2022.
Clinical Microbiology and Infection
23.11.2022
To evaluate the activity of cefiderocol against sequential P. aeruginosa isolates from chronically-infected cystic fibrosis (CF) patients as well as to investigate the potential mechanisms involved in resistance through whole genome sequencing.
Antimicrobial Agents And Chemotherapy
15.11.2022
Antimicrobial Agents and Chemotherapy, Ahead of Print.
Antimicrobial Agents And Chemotherapy
26.10.2022
Antimicrobial Agents and Chemotherapy, Ahead of Print.
Antimicrobial Agents And Chemotherapy
26.10.2022
Antimicrobial Agents and Chemotherapy, Ahead of Print.
Clinical Microbiology and Infection
14.10.2022
This study aimed to characterize a novel KPC-113 variant from a clinical Pseudomonas aeruginosa isolate R20-14.
International Journal of Infectious Diseases
13.10.2022
: We evaluated the activity of ceftolozane/tazobactam and comparators against clinical Pseudomonas aeruginosa isolates collected for the global SMART surveillance program in ten countries in the Middle East and Africa to augment scarce standardized surveillance data in this region.
Infection and Immunity
28.09.2022
Infection and Immunity, Ahead of Print.
Emerging Infectious Diseases
21.09.2022
Dispatch - Dialysis Water Supply Faucet as Reservoir for Carbapenemase-Producing Pseudomonas aeruginosa
Clinical Infectious Diseases
21.09.2022
AbstractRecommended antimicrobial treatment durations for ventilator-associated pneumonia (VAP) caused by Pseudomonas aeruginosa have evolved over the past few decades. In this Viewpoint, we provide a narrative review of landmark trials investigating antimicrobial treatment durations for VAP caused by P. aeruginosa, and appraise iterations of expert consensus guidelines based on these data. We highlight strengths and weaknesses of existing data on this topic and provide recommendations for future avenues of
Infection and Immunity
20.09.2022
Infection and Immunity, Ahead of Print.
Aktuelle smitsomme sygdomme [15]
ProMED
18.03.2023
P. aeruginosa -- United States'As of 14 Mar 2023, CDC, in partnership with state and local health departments, identified 68 patients in 16 states (CA, CO, CT, FL, IL, NC, NJ, NM, NY, NV, PA, SD, TX, UT, WA, WI) with VIM-GES-CRPA, a rare strain of extensively drug-resistant _P. aeruginosa_. Thirty-seven patients were linked to 4 healthcare facility clusters. One person has died and there have been 8 reports of vision loss and 4 reports of enucleation (surgical removal of eyeball). Dates of specimen collecti
ProMED
8.02.2023
nosa -- United StatesThe Food and Drug Administration (FDA) has warned against using 'Artificial Tears' eye drops produced by a Tamil Nadu-based firm after an outbreak of drug-resistant infections was linked to the drug in the USA. This is the 3rd such controversy involving an Indian pharma company.Another controversy has hit India's pharmaceutical industry as the United States warned that an eye drop manufactured by a Tamil Nadu-based firm has caused an outbreak of the drug-resistant bacterium _Pseudomonas
ProMED
4.02.2023
P. aeruginosa -- United StatesPatients should stop using EzriCare Artificial Tears pending additional information and guidance from CDC and FDA. If patients were advised to use EzriCare Artificial Tears by their healthcare provider, they should follow up with their healthcare provider for recommendations about alternative treatment options. Patients who have used EzriCare preservative-free artificial tears and who have signs or symptoms of an eye infection should seek medical care immediately. At this time,
ProMED
2.02.2023
P. aeruginosa -- United StatesOne person has died and at least 3 others are left with permanent vision loss because of a bacterial infection possibly linked to a brand of over-the-counter eyedrops, according to the Centers for Disease Control and Prevention (CDC). A majority of those affected reported using preservative-free EzriCare Artificial Tears before becoming ill, CDC reported in a statement dated 20 Jan 2023. While the infections have not been definitively traced to the eyedrops, CDC recommended tha
ProMED
8.05.2022
Hospital-Related Infection -- Norway
Eurosurveillance latest updates
5.05.2022
In November 2021, a clonal outbreak of Pseudomonas aeruginosa of novel sequence type ST3875 was detected in three patients who died of bloodstream infections in one hospital. By 25 April 2022, the outbreak included 339 cases from 38 hospitals across Norway. Initial hospital reports indicate Pseudomonas infection as the main contributing cause in seven deaths. In March 2022, the outbreak strain was identified in non-sterile pre-moistened disposable washcloths, used to clean patients, from three lots from the
ProMED
19.04.2022
P. aeruginosa -- Bangladesh
Morbidity and Mortality Weekly Report (MMWR)
23.05.2019
Verona integron-encoded metallo-β-lactamase-producing carbapenem-resistant Pseudomonas aeruginosa and other carbapenemase-producing organisms represent an emerging U.S. public health threat.
Morbidity and Mortality Weekly Report (MMWR)
31.05.2018
Eurosurveillance latest updates
5.05.2022
In November 2021, a clonal outbreak of Pseudomonas aeruginosa of novel sequence type ST3875 was detected in three patients who died of bloodstream infections in one hospital. By 25 April 2022, the outbreak included 339 cases from 38 hospitals across Norway. Initial hospital reports indicate Pseudomonas infection as the main contributing cause in seven deaths. In March 2022, the outbreak strain was identified in non-sterile pre-moistened disposable washcloths, used to clean patients, from three lots from the
Eurosurveillance latest updates
8.09.2022
and caused by Pseudomonas aeruginosa (6.2% vs 2.0%), fungi (2.9% vs 1.4%) and multidrug-resistant (MDR) pathogens (2.2% vs 1.8%), which were also predictors of death within 2 days in the model. . . Conclusions. Overrepresentation of polymicrobial, fungal, P. aeruginosa and MDR aetiology among BSI leading to early death is challenging concerning the initial antimicrobial treatment. Our findings highlight the need for active prevention and prompt recognition of BSI and appropriate antimicrobial treatment.
Eurosurveillance latest updates
5.05.2022
In November 2021, a clonal outbreak of Pseudomonas aeruginosa of novel sequence type ST3875 was detected in three patients who died of bloodstream infections in one hospital. By 25 April 2022, the outbreak included 339 cases from 38 hospitals across Norway. Initial hospital reports indicate Pseudomonas infection as the main contributing cause in seven deaths. In March 2022, the outbreak strain was identified in non-sterile pre-moistened disposable washcloths, used to clean patients, from three lots from the
Eurosurveillance latest updates
18.11.2021
ncluding meticillin-resistant Staphylococcus aureus (MRSA), glycopeptide-resistant enterococci (GRE), extended-spectrum cephalosporin-resistant Escherichia coli (ESCR-EC) and Klebsiella pneumoniae (ESCR-KP), carbapenem-resistant Enterobacterales (CRE) and Pseudomonas aeruginosa (CRPA) from Swiss ICU. We assessed time trends of antibiotic consumption and identified factors associated with CRE and CRPA. Methods We analysed patient isolate and antibiotic consumption data of Swiss ICU sent to the Swiss Centr
Eurosurveillance latest updates
30.09.2021
d; among those, 163 (78.4%) carried ESBL-PE, 28 (13.5%) MDR Acinetobacter species, 25 (12.0%) meticillin-resistant Staphylococcus aureus, 25 (12.0%) vancomycin-resistant Enterococcus, 14 (6.7%) carbapenemase-producing Enterobacteriaceae, and 12 (5.8%) MDR Pseudomonas aeruginosa; 46 strains tested carbapenemase gene-positive. In multivariable analysis, geographical region, intensive care unit (ICU) treatment and antibiotic use abroad proved to be risk factors for colonisation. Clinical MDR infections, two of
Morbidity and Mortality Weekly Report (MMWR)
23.05.2019
Verona integron-encoded metallo-β-lactamase-producing carbapenem-resistant Pseudomonas aeruginosa and other carbapenemase-producing organisms represent an emerging U.S. public health threat.